Shares in AbbVie slumped by double digits Monday after the company disclosed its psychiatric medicine emraclidine didn’t best ...

AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US ...

A federal judge heard final arguments on Friday as to whether or not a mentally ill arson suspect should be forcibly medicated to try and make him competent to stand trial for a 2021 fire in ...

The state auditor report found poor record keeping and a lack of therapy to accompany psychotropic medications.

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Acadia Pharmaceuticals Inc. has persuaded a federal judge to trim claims from investment funds that said the drugmaker misled them into thinking an antipsychotic drug was poised for expanded use , ...

Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday.

1 When a patient stops taking the culpable medication, symptoms may persist ... 1 Approximately 20% of people who take certain older antipsychotic medications may develop tardive dyskinesia ...